ClinicalTrials.gg
CompletedNCT03022097AVANTUpdated Mar 26, 2025Results posted

Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients

A Phase 3 interventional study of Aclidinium bromide/formoterol Fixed-Dose Combination and Aclidinium bromide in COPD, sponsored by AstraZeneca. Completed at 75 sites in 5 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,625
Allocation
Randomized
Ages
40 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. aclidinium bromide · Pulmonary Disease, Chronic Obstructive.

Enrollment
4th of 27
1,625 · median 561
Started
2017
with 1 other
Phase 3
19 of 28
none open now
Registered
27th of 28
by date
Lead sponsor
25 of 28
AstraZeneca

Among the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive, this one is the 4th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2017, is one of 19 in phase 3, and was the 27th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About aclidinium bromide

aclidinium bromide: first FDA approval 2012 (TUDORZA PRESSAIR), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Adult male or non-pregnant, non-lactating female patients aged ≥40
    1. Patients with a diagnosis of prior to Visit 1 (screening)
    1. Patients with moderate to severe stable COPD (Stage II or Stage III) at Visit 1: post-bronchodilator ≥30% and \< 80% and post-bronchodilator FEV1/Forced vital capacity (FVC) \< 70%
    1. Current or former smokers with a smoking history of ≥ 10 pack-years
    1. Patients able to perform repeatable pulmonary function testing for FEV1 according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2005 criteria at Visit 1(screening)
    1. Patients who understand the study procedures and are willing to participate in the study as indicated by signing the

Exclusion criteria

Exclusion Criteria:

    1. Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff) or patients employed by or relatives of the employees of the site or sponsor.
    1. Previous enrolment or randomisation in the present study
    1. History or current diagnosis of asthma
    1. Any respiratory tract infection (including the upper respiratory tract) or exacerbation (including the mild COPD exacerbation) within 6 weeks prior to screening or during the run-in period
    1. Patients hospitalized for COPD exacerbation (an emergency room visit for longer than 24 hours will be considered a hospitalization) within 3 months prior to screening and during the run-in period
    1. respiratory conditions other than COPD
    1. Patients who in the Investigator's opinion may need to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to screening
    1. Use of long-term oxygen therapy (≥15 hours/day)
    1. Patient who does not maintain regular day/night, waking/sleeping cycles including night shift workers
    1. Clinically significant cardiovascular conditions
    1. Patients with Type I or uncontrolled Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension
    1. Patients with corrected interval (QTc) using Fridericia formula (QTcF) (QTc=QT/ Duration in milliseconds between two R peaks of two consecutive QRS complexes (RR1/3) >470 msec as indicated in the centralised reading report assessed at Screening (Visit 1)
    1. Patients with clinically significant abnormalities in the clinical laboratory tests, parameters (other than QTcF) or in the physical examination at Visit 1 (screening)
    1. Patients with abnormal liver function tests defined as (AST), Alanine aminotransferase (ALT), or total ≥ 2.5 times ranges at screening
    1. Patient with known non-controlled history of infection with and/or active hepatitis
    1. Patient with a history of reaction to inhaled anticholinergic drugs, sympathomimetic amines, inhaled medication or any component thereof
    1. Patient with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic non-stable prostatic hypertrophy
    1. History of of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer
    1. Any other serious or uncontrolled physical or mental dysfunction
    1. Patients with a history (within 2 years prior to Visit 1 (screening) of drug and/or alcohol abuse that may prevent study compliance based on the Investigator judgment
    1. Patients unlikely to be cooperative or cannot comply with the study procedures
    1. Patients treated with any drug within 30 days (or 6 half-lives, whichever is longer) prior to screening
    1. Patients who intended to use any concomitant medication not permitted by this protocol or who had not undergone the required for a particular prohibited medication
    1. Patients unable to give consent, or patients of consenting age but under guardianship, or vulnerable patients
    1. Any other conditions that, in the Investigator's opinion, might have indicated the patient to be unsuitable for the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,625 participants (actual)

Study arms

  • Experimental
    Experimental 1

    Aclidinium bromide 400μg/Formoterol fumarate 12 μg

    Drug: Aclidinium bromide/formoterol Fixed-Dose Combination

  • Experimental
    Experimental 2

    Aclidinium bromide 400 μg

    Drug: Aclidinium bromide

  • Active comparator
    Comparator

    Formoterol fumarate 12 μg

    Drug: Formoterol Fumarate

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugAclidinium bromide/formoterol Fixed-Dose Combination

    Drug pages: Aclidinium bromide · Formoterol

    Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair

  • Inhaled Aclidinium bromide 400 μg, twice per day via Genuair

  • Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler

  • DrugPlacebo

    Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1)

    Change from baseline in 1-hour morning post-dose FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Aclidinium bromide at Week 24. Baseline was defined as the average of the two FEV1 values measure prior to the administration of the first dose of the IP at randomisation visit. If one of the two values was missing, the available one was used as baseline. If both values were missing, the screening pre-bronchodilator value was used. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

    Time frame: Week 24, 1-hour morning post-dose

  2. Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate

    Change from baseline in morning pre-dose (trough) FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Formoterol fumarate 12 μg at Week 24. Morning pre-dose (trough) FEV1 was defined as the average of the two FEV1 values at morning pre-dose of IP at Week 24. If one value was missing, the remaining was used as the trough value. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

    Time frame: Week 24, morning pre-dose (trough)

  3. Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide

    Change from baseline in morning pre-dose (trough) FEV1 of Aclidinium bromide 400 μg compared to placebo at Week 24. Morning pre-dose (trough) FEV1 was defined as the average of the two FEV1 values at morning pre-dose of IP at Week 24. If one value was missing, the remaining was used as the trough value. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

    Time frame: Week 24, morning pre-dose (trough)

Secondary outcomes

  1. Change From Baseline in Peak FEV1

    Change from baseline in peak FEV1 of Aclidinium bromide 400 μg compared to placebo at week 24. Peak FEV1 was the highest value recorded at Week 24 after morning IP intake. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

    Time frame: Week 24, peak

  2. Improvements Transition Dyspnoea Index (TDI) Focal Score

    Improvements TDI focal score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24. Transition Dyspnoea Index (TDI) measures severity of breathlessness in symptomatic patients. An impairment severity score is assigned for three components: functional impairment; magnitude of task and magnitude of effort. Focal scores is derived as the sum of individual component scores. TDI focal score ranges from -9 to +9, with negative values indicating a worsening in dyspnoea, 0 showing no change from baseline and positive values associated with a post-baseline improvement. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

    Time frame: Week 24

  3. Change From Baseline in St Georges Respiratory Questionnaire (SGRQ) Total Score

    Change from baseline in SGRQ total score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24. St. George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life and perceived well-being. It is composed of 50 items split into 17 parts, from which 3 dimension scores on Symptoms, Activity and Impact are derived. A total score utilising responses to all items can also be derived to assess the overall impact of COPD on quality of life. SGRQ dimension and total scores range from 0 to 100, with higher scores indicating a worse possible health status. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

    Time frame: Week 24

07

Results

Posted Mar 26, 2025

Participant flow

The study was conducted at 81 study centers in 5 countries China(50), India (15), Philippines (8), Taiwan (3) and Vietnam (5) between 02 February 2017 and 14 April 2022

Participant flow — Overall Study
MilestoneAB/FF 400/12 μgAB 400 μgFF 12 μgPlacebo
Started265267265269
Received treatment263266264269
Received treatment with a baseline fev1262265259267
Completed treatment243247230230
Completed244248233235
Not completed21193234
Withdrew: Adverse event3413
Withdrew: Progressive disease2052
Withdrew: Lack of efficacy0033
Withdrew: Protocol violation1010
Withdrew: Withdrawal by subject11131521
Withdrew: Lost to follow-up0011
Withdrew: Other4164
Withdrew: Due to covid-19 pandemic0100

Outcome measures

PrimaryChange From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1)

Change from baseline in 1-hour morning post-dose FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Aclidinium bromide at Week 24. Baseline was defined as the average of the two FEV1 values measure prior to the administration of the first dose of the IP at randomisation visit. If one of the two values was missing, the available one was used as baseline. If both values were missing, the screening pre-bronchodilator value was used. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

Time frame:
Week 24, 1-hour morning post-dose
Reported as:
Least squares mean · Litres
Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1)
LitresAB/FF 400/12 μgAB 400 μgFF 12 μgPlacebo
Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1)0.248 ± 0.0130.156 ± 0.0130.138 ± 0.013-0.050 ± 0.013
Statistical analysis
  • AB/FF 400/12 μg vs AB 400 μg · Mixed Models Analysis · p = <0.001 (Pre-specified hierarchical sequence of testing used to adjust for multiplicity.) · Least squares mean difference: 0.092 · 95% CI 0.060 to 0.124Screening pre- and post-bronchodilator FEV1, age, baseline FEV1 as covariates; treatment, country, smoking, visit and group-by-visit as factors.
PrimaryChange From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate

Change from baseline in morning pre-dose (trough) FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Formoterol fumarate 12 μg at Week 24. Morning pre-dose (trough) FEV1 was defined as the average of the two FEV1 values at morning pre-dose of IP at Week 24. If one value was missing, the remaining was used as the trough value. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

Time frame:
Week 24, morning pre-dose (trough)
Reported as:
Least squares mean · Litres
Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate
LitresAB/FF 400/12 μgAB 400 μgFF 12 μgPlacebo
Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate0.081 ± 0.0140.050 ± 0.014-0.004 ± 0.014-0.084 ± 0.014
Statistical analysis
  • AB/FF 400/12 μg vs FF 12 μg · Mixed Models Analysis · p = <0.001 (Pre-specified hierarchical sequence of testing used to adjust for multiplicity.) · Least squares mean difference: 0.085 · 95% CI 0.053 to 0.117Screening pre- and post-bronchodilator FEV1, age, baseline FEV1 as covariates; treatment, country, smoking, visit and group-by-visit as factors.
PrimaryChange From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide

Change from baseline in morning pre-dose (trough) FEV1 of Aclidinium bromide 400 μg compared to placebo at Week 24. Morning pre-dose (trough) FEV1 was defined as the average of the two FEV1 values at morning pre-dose of IP at Week 24. If one value was missing, the remaining was used as the trough value. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

Time frame:
Week 24, morning pre-dose (trough)
Reported as:
Least squares mean · Litres
Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide
LitresAB/FF 400/12 μgAB 400 μgFF 12 μgPlacebo
Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide0.081 ± 0.0140.050 ± 0.014-0.004 ± 0.014-0.084 ± 0.014
Statistical analysis
  • AB 400 μg vs Placebo · Mixed Models Analysis · p = <0.001 (Pre-specified hierarchical sequence of testing used to adjust for multiplicity.) · Least squares mean difference: 0.134 · 95% CI 0.103 to 0.166Screening pre- and post-bronchodilator FEV1, age, baseline FEV1 as covariates; treatment, country, smoking, visit and group-by-visit as factors.
SecondaryChange From Baseline in Peak FEV1

Change from baseline in peak FEV1 of Aclidinium bromide 400 μg compared to placebo at week 24. Peak FEV1 was the highest value recorded at Week 24 after morning IP intake. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

Time frame:
Week 24, peak
Reported as:
Least squares mean · Litres
Change From Baseline in Peak FEV1
LitresAB/FF 400/12 μgAB 400 μgFF 12 μgPlacebo
Change From Baseline in Peak FEV10.324 ± 0.0130.225 ± 0.0130.191 ± 0.0140.008 ± 0.014
Statistical analysis
  • AB 400 μg vs Placebo · Mixed Models Analysis · p = <0.001 (Pre-specified hierarchical sequence of testing used to adjust for multiplicity.) · Least squares mean difference: 0.217 · 95% CI 0.184 to 0.250Screening pre- and post-bronchodilator FEV1, age, baseline FEV1 as covariates; treatment, country, smoking, visit and group-by-visit as factors.
SecondaryImprovements Transition Dyspnoea Index (TDI) Focal Score

Improvements TDI focal score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24. Transition Dyspnoea Index (TDI) measures severity of breathlessness in symptomatic patients. An impairment severity score is assigned for three components: functional impairment; magnitude of task and magnitude of effort. Focal scores is derived as the sum of individual component scores. TDI focal score ranges from -9 to +9, with negative values indicating a worsening in dyspnoea, 0 showing no change from baseline and positive values associated with a post-baseline improvement. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

Time frame:
Week 24
Reported as:
Least squares mean · Units on a scale
Improvements Transition Dyspnoea Index (TDI) Focal Score
Units on a scaleAB/FF 400/12 μgAB 400 μgFF 12 μgPlacebo
Improvements Transition Dyspnoea Index (TDI) Focal Score2.9 ± 0.22.6 ± 0.22.4 ± 0.22.1 ± 0.3
Statistical analysis
  • AB/FF 400/12 μg vs Placebo · Mixed Models Analysis · p = 0.005 (Pre-specified hierarchical sequence of testing used to adjust for multiplicity.) · Least squares mean difference: 0.8 · 95% CI 0.2 to 1.3BDI, age as covariates; treatment, country, smoking, visit and group-by-visit as factors.
  • AB 400 μg vs Placebo · Mixed Models Analysis · p = 0.132 (Pre-specified hierarchical sequence of testing used to adjust for multiplicity.) · Least squares mean difference: 0.4 · 95% CI -0.1 to 1.0BDI, age as covariates; treatment, country, smoking, visit and group-by-visit as factors.
SecondaryChange From Baseline in St Georges Respiratory Questionnaire (SGRQ) Total Score

Change from baseline in SGRQ total score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24. St. George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life and perceived well-being. It is composed of 50 items split into 17 parts, from which 3 dimension scores on Symptoms, Activity and Impact are derived. A total score utilising responses to all items can also be derived to assess the overall impact of COPD on quality of life. SGRQ dimension and total scores range from 0 to 100, with higher scores indicating a worse possible health status. Estimand is based on the while on-treatment approach, where treatment estimates are analysed while subjects are taking IP.

Time frame:
Week 24
Reported as:
Least squares mean · Units on a scale
Change From Baseline in St Georges Respiratory Questionnaire (SGRQ) Total Score
Units on a scaleAB/FF 400/12 μgAB 400 μgFF 12 μgPlacebo
Change From Baseline in St Georges Respiratory Questionnaire (SGRQ) Total Score-8.7 ± 1.2-7.6 ± 1.2-7.2 ± 1.2-4.7 ± 1.2
Statistical analysis
  • AB/FF 400/12 μg vs Placebo · Mixed Models Analysis · p = 0.003 (Pre-specified hierarchical sequence of testing used to adjust for multiplicity. P-value is nominal.) · Least squares mean difference: -4.0 · 95% CI -6.7 to -1.4Baseline SGRQ, age as covariates; treatment, country, smoking, visit and group-by-visit as factors.
  • AB 400 μg vs Placebo · Mixed Models Analysis · p = 0.031 (Pre-specified hierarchical sequence of testing used to adjust for multiplicity. P-value is nominal.) · Least squares mean difference: -2.9 · 95% CI -5.5 to -0.3Baseline SGRQ, age as covariates; treatment, country, smoking, visit and group-by-visit as factors.

Adverse events

Collected over From time of signature of informed consent throughout the treatment period and including the follow-up period (2 weeks after last IP dose), on average 26 weeks. Only treatment-emergent AEs are reported in the tables below.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AB/FF 400/12 μg0/263 (0%)19/263 (7.2%)53/263 (20.2%)
AB 400 μg0/266 (0%)21/266 (7.9%)44/266 (16.5%)
FF 12 μg1/264 (0.4%)26/264 (9.8%)54/264 (20.5%)
Placebo2/269 (0.7%)21/269 (7.8%)55/269 (20.4%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventAB/FF 400/12 μgAB 400 μgFF 12 μgPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders9/2636/26610/2647/269
PneumoniaInfections and infestations2/2633/2665/2644/269
Acute myocardial infarctionCardiac disorders0/2630/2662/2640/269
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/2632/2660/2640/269
Lower respiratory tract infectionInfections and infestations1/2630/2660/2641/269
Postoperative wound infectionInfections and infestations1/2630/2660/2640/269
SepsisInfections and infestations1/2630/2660/2640/269
Benign neoplasm of adrenal glandNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2630/2660/2640/269
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2630/2660/2640/269
Cerebral arteriosclerosisNervous system disorders1/2630/2660/2640/269
Most frequent other events
Most frequent other events
EventAB/FF 400/12 μgAB 400 μgFF 12 μgPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders25/26321/26633/26435/269
Upper respiratory tract infectionInfections and infestations31/26325/26624/26424/269

Baseline characteristics

Safety population comprising all participants randomised to a treatment group who received at least one dose of double-blind investigational treatment (Safety Analysis Set).

Age, Continuous
Age, Continuous(Years)AB/FF 400/12 μgAB 400 μgFF 12 μgPlaceboTotal
Mean65.3 ± 7.165.4 ± 6.865.4 ± 7.664.9 ± 6.965.2 ± 7.1
Sex/Gender, Customized
Sex/Gender, Customized(Participants)AB/FF 400/12 μgAB 400 μgFF 12 μgPlaceboTotal
Male2562542512561017
Female712131345
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AB/FF 400/12 μgAB 400 μgFF 12 μgPlaceboTotal
American Indian or Alaska Native00000
Asian2632662642691062
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AB/FF 400/12 μgAB 400 μgFF 12 μgPlaceboTotal
Chinese186186187188747
Taiwanese334414
Vietnamese101091039
Indian35373537144
Filipino29302930118
Pre-bronchodilator FEV1 at screening
Pre-bronchodilator FEV1 at screening(Litres)AB/FF 400/12 μgAB 400 μgFF 12 μgPlaceboTotal
Mean1.187 ± 0.4041.192 ± 0.3851.199 ± 0.4151.212 ± 0.3831.197 ± 0.396
Post-bronchodilator FEV1 at screening
Post-bronchodilator FEV1 at screening(Litres)AB/FF 400/12 μgAB 400 μgFF 12 μgPlaceboTotal
Mean1.356 ± 0.4201.363 ± 0.3901.366 ± 0.4471.385 ± 0.4081.367 ± 0.416
Baseline FEV1
Baseline FEV1(Litres)AB/FF 400/12 μgAB 400 μgFF 12 μgPlaceboTotal
Mean1.182 ± 0.4151.178 ± 0.3811.169 ± 0.4131.184 ± 0.3991.178 ± 0.402
Smoking status
Smoking status(Participants)AB/FF 400/12 μgAB 400 μgFF 12 μgPlaceboTotal
Current smoker84858685340
Former smoker179181178184722

1 further baseline measures are reported on the registry.

08

Study locations

75 sites
  • Research Site
    Baotou, 14010, China
  • Research Site
    Beijing, 100050, China
  • Research Site
    Beijing, 100097, China
  • Research Site
    Beijing, 102300, China
  • Research Site
    Beijing, CN-100083, China
  • Research Site
    Cangzhou, 61000, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410005, China
  • Research Site
    Changsha, 430033, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Guangzhou, 510530, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310005, China
  • Research Site
    Hangzhou, 310014, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hefei, 230022, China
  • Research Site
    Hefei, 230061, China
  • Research Site
    Hengyang, 50012, China
  • Research Site
    Hohhot, 010017, China
  • Research Site
    Liangyugang, 222002, China
  • Research Site
    Linhai, 317000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Qiqihar, 161005, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Shanghai, 200062, China
  • Research Site
    Shanghai, 200090, China
  • Research Site
    Shanghai, 200240, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Shanghai, 201200, China
  • Research Site
    Shanxi, 30001, China
  • Research Site
    Shengyang, 110004, China
  • Research Site
    Shenzhen, 518020, China
  • Research Site
    Shenzhen, 518053, China
  • Research Site
    Shijiazhuang, 050000, China
  • Research Site
    Taiyuan, 030001, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Wenzhou, 325015, China
  • Research Site
    Wuxi, 214023, China
  • Research Site
    Xiamen, 361004, China
  • Research Site
    Xian, 710061, China
  • Research Site
    Xining, 810007, China
  • Research Site
    Yangzhou, 225000, China
  • Research Site
    Yanji, 133000, China
  • Research Site
    Yinchuan, 750004, China
  • Research Site
    Zhanjiang, 524001, China
  • Research Site
    Ahmedabad, 380060, India
  • Research Site
    Alappuzha, 688524, India
  • Research Site
    Ernakulam, 683577, India
  • Research Site
    Guntur, 522001, India
  • Research Site
    Jaipur, 302006, India
  • Research Site
    Kozhikode, 673008, India
  • Research Site
    Mysore, 57002, India
  • Research Site
    Nagpur, 440010, India
  • Research Site
    Nagpur, 440012, India
  • Research Site
    Nagpur, 440019, India
  • Research Site
    Pune, 411019, India
  • Research Site
    Pune, 411057, India
  • Research Site
    Pune, 440012, India
  • Research Site
    Vijayawada, 520 008, India
  • Research Site
    Caloocan City, 1400, Philippines
  • Research Site
    Iloilo City, 5000, Philippines
  • Research Site
    Manila, 1000, Philippines
  • Research Site
    Quezon City, 1000, Philippines
  • Research Site
    Quezon City, 1100, Philippines
  • Research Site
    Quezon City, 1101, Philippines
  • Research Site
    Keelung, 20448, Taiwan
  • Research Site
    Taichung, 40201, Taiwan
  • Research Site
    Taipei, 112, Taiwan
  • Research Site
    Hanoi, 10000, Vietnam
  • Research Site
    Ho Chi Minh City, 700000, Vietnam
  • Research Site
    Ho Chi Minh City, 70000, Vietnam
  • Research Site
    Ho Chi Minh, 70000, Vietnam
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Apr 2022, 62 months.

Results were first posted in Mar 2025, 2 years 11 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 62 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2017
First posted
Jan 16, 2017
StartActual
Feb 2, 2017
Primary completionActual
Apr 14, 2022
CompletionActual
Apr 14, 2022
Results first posted
Mar 26, 2025
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03022097
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jan 16, 2017
Start date
Feb 2, 2017
Primary completion
Apr 14, 2022
Completion
Apr 14, 2022
Results posted
Mar 26, 2025
Last update
Mar 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aclidinium bromide · Formoterol

Start the discussion